“Onco360 is grateful for the opportunity to partner with the Regeneron team and become a specialty pharmacy provider for Lynozyfic,” said Benito Fernandez, Chief Commercial Officer.“We are proud to ...

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Regeneron ...

Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Q2 2025 Management View CEO Leonard S. Schleifer reported "Regeneron delivered a strong second quarter, driven by durable ...

New FDA approvals in July include therapies for NSCLC, relapsed multiple myeloma, liver cancer, and B-cell malignancies.

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased ...

On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Regeneron's Lynozyfic ...

Regeneron Pharmaceuticals (REGN) is gearing up for an earnings announcement that could pivot its stock's current trajectory.